The review synthesizes how several psychoactive compound classes interact with skin biology through neurochemical and immunomodulatory pathways, positioning cannabinoids, antidepressants, and psychedelics side by side as an emerging area connecting neuropharmacology and dermatology.

For cannabinoids specifically, the authors describe THC as showing anti-inflammatory, antipruritic, and anti-aging properties when applied topically in the literature they reviewed, and frame this as therapeutic potential worth further study rather than an established treatment.

This is a narrative review, not a systematic review, meta-analysis, or randomized controlled trial. It draws together mechanistic and preclinical findings rather than pooling controlled human outcome data for a specific topical THC formulation.

The cannabinoid section sits alongside separate discussions of antidepressants and psychedelics in skin biology, underscoring that the paper’s scope is broad cutaneous pharmacology, not a dedicated cannabis clinical trial report.

Mechanistic and preclinical evidence for anti-inflammatory or antipruritic effects does not automatically translate into a reliable clinical effect at consumer-accessible topical doses, concentrations, and formulations.

Narrative reviews are valuable for generating hypotheses and organizing a scattered literature, but they do not control for publication bias, do not grade certainty of evidence the way a systematic review or GRADE assessment would, and can overstate translational readiness if read as clinical guidance.

A patient asking whether a topical CBD or THC cream will help their eczema, psoriasis flare, or itch deserves an honest answer: there is a real, biologically plausible mechanism worth taking seriously, and there is not yet a body of controlled human trials proving a specific product works for a specific diagnosis.

That combination, plausible mechanism plus thin clinical proof, is common in cannabis dermatology and deserves to be communicated exactly that way rather than rounded up to a treatment claim.

Topical cannabinoid marketing often moves faster than the underlying clinical trial evidence, borrowing credibility from preclinical and mechanistic findings without noting the gap between cutaneous biology research and a validated finished product.

A more defensible reading treats this review as a signal that topical cannabinoid dermatology deserves controlled human research, not as evidence that the research has already been done.

I find this review useful precisely because it is honest about scope. Placing THC next to fluoxetine and psilocybin as compounds with plausible skin-level mechanisms is a legitimate way to organize an emerging field, and the anti-inflammatory and antipruritic mechanisms described for THC track with what I would expect from what we know about cutaneous cannabinoid receptor signaling.

What I will not do is let a mechanistic review stand in for a clinical trial when a patient asks if a topical product will resolve their skin condition. My answer stays the same either way: the biological rationale for topical cannabinoids in inflammatory and itch-related skin problems is genuinely interesting, and the clinical proof for any specific over-the-counter product is still thin. Both of those things are true at once, and patients deserve to hear both.

A Four-Step Reading Frame